Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients
Authors:
- 23 March 2022
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 43 (2) , 76-85
Abstract
Tacrolimus is widely used in organ transplantation to prevent rejection. However, the narrow therapeutic window and the large inter‐and intra‐individual variability in the pharmacokinetics (PK) of tacrolimus make it difficult for individualization of dosing. This study aimed at developing a population pharmacokinetic model for estimating the oral clearance of tacrolimus in Chinese liver transplant patients, and identifying factors that contribute to the PK variability of tacrolimus. Data of 151 liver transplant patients who received tacrolimus were analyzed in this study. The population PK model was analyzed and the covariates including population demographic and biochemical characteristics, drug combination, and genetic polymorphism were explored using non‐linear mixed‐effects modeling approach. A single‐compartment population PK model was developed, and the final model was CL/F = (14.6–2.38 × cytochrome P450 (CYP) 3A5−3.72 × WZC+1.04 × (POD/9)+2.48 × COR) × Exp(ηi), where CYP3A5 was 1 for CYP3A5*3/*3, Wuzhi Capsule (WZC) was 1 when patients took tacrolimus combined with WZC, otherwise it was 0, corticosteroids (COR) was 1 when patients take tacrolimus combined with COR, otherwise, it was 0, POD was the post‐operative day. Visual inspection and bootstrap indicated that the final model was stable and robust. In this study, we developed the first tacrolimus population PK model in Chinese adult liver transplant patients. We first determined the influence of WZC on tacrolimus in these people, which could provide useful PK information for the drug combination of tacrolimus and WZC. We also revealed the influence of genetic polymorphism of CYP3A5, POD, and a combination of COR on tacrolimus PK. Therefore, these significant factors should be taken into consideration in optimizing dosage regimens.Keywords
Funding Information
- National Natural Science Foundation of China (81303113)
This publication has 50 references indexed in Scilit:
- Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplantExpert Opinion on Drug Safety, 2010
- Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506)International Journal of Pharmaceutics, 2010
- Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplantBritish Journal of Clinical Pharmacology, 2009
- Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry methodBiomedical Chromatography, 2009
- Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patientsPharmacogenetics and Genomics, 2008
- Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patientsJournal of Clinical Pharmacy and Therapeutics, 2007
- Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteersBritish Journal of Clinical Pharmacology, 2007
- Cytochrome P450 3A4 and P-glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent DiarrheaAmerican Journal of Transplantation, 2005
- IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACTDrug Metabolism and Disposition, 2004
- Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantationLiver Transplantation, 2003